B‑Cell Lymphoblastic Leukemia Monitoring, Measurable/Minimal Residual Disease Detection, Flow Cytometry, Varies
Use
This test is appropriate only for patients with a previously confirmed diagnosis of B‑cell acute lymphoblastic leukemia (B‑ALL) and is used to monitor minimal residual disease (MRD) with high sensitivity (down to 0.002%), thus providing important prognostic information following therapy including induction or transplant. Immunophenotyping helps establish an immunophenotypic fingerprint of tumor cells to guide monitoring post-therapy or transplant. ([mayocliniclabs.com](https://www.mayocliniclabs.com/test-catalog/overview/608251?utm_source=openai))
Special Instructions
Not provided.
Limitations
Test is only appropriate for patients with a previously confirmed diagnosis of B‑ALL. Treatment with anti‑CD19 antibodies may interfere with MRD detection. Gross hemolysis in the specimen may result in rejection. ([mayocliniclabs.com](https://www.mayocliniclabs.com/test-catalog/overview/608251?utm_source=openai))
New York Approved
Methodology
Cell-based / Cytometry
Biomarkers
LOINC Codes
- 102084-1 - BCell Lym LK monitor MRD det Bld/Mar FC
- 22637-3 - Path report.final Dx Spec
- 30954-2 - Relevant dx tests/lab data note
- 22635-7 - Path report.microscopic Spec Other Stn
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
6 mL
Minimum Volume
2 mL
Container
Preferred: Yellow top (ACD solution A or B); Acceptable: Lavender top (EDTA)
Collection Instructions
Send in original tube; do not aliquot; label as whole blood
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Ambient 72 hours |